Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 909,800 shares, a growth of 1,344.1% from the November 30th total of 63,000 shares. Based on an average daily trading volume, of 461,600 shares, the days-to-cover ratio is presently 2.0 days.
NASDAQ IPHA traded up $0.05 on Thursday, hitting $2.11. 41,706 shares of the stock were exchanged, compared to its average volume of 127,127. The company's 50-day moving average price is $1.80 and its two-hundred day moving average price is $2.05. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51.
A number of research analysts have recently commented on IPHA shares. Evercore ISI raised Innate Pharma to a "strong-buy" rating in a report on Monday, September 16th. HC Wainwright reissued a "buy" rating and set a $11.50 target price on shares of Innate Pharma in a research note on Monday, December 9th.
Check Out Our Latest Report on Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Innate Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.
While Innate Pharma currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.